Scientific resource
Poster
Poster
03/04/2023
Preclinical evaluation of a chimpanzee adenovirus vector expressing a pre-fusion Spike (BV-AdCoV-1) SARS-CoV-2 intranasal vaccine candidate in golden Syrian hamsters
Download the e-poster and learn more about Chimpanzee Adenovirus vector SARS-CoV-2 intranasal Vaccine Candidate from Oncodesign Services.
Poster
28/03/2023
New target identification and validation platform combining AI in oncology and preclinical pharmacology
The OncoSNIPE® project combines Ai in Oncology and Preclinical Pharmacology to develop a new identification and validation platform. Learn more here
Poster
28/03/2023
DRIVE-Biologics: all the steps from discovery to development of novel biological therapeutics
DRIVE-Biologics aims to optimize your biologics therapeutics and drug discovery through stages of preclinical evaluation to clinical studies. Learn more here
Poster
28/03/2023
Simultaneous 18F-FDG PET / MR imaging for metastases identification in a disseminated human preclinical melanoma model
Simultaneous 18F-FDG PET / MR imaging for metastases identification in a disseminated human preclinical Melanoma Model. Learn more here
Poster
28/03/2023
OncoTAM, a comprehensive preclinical platform to explore macrophages
OncoTAM targets Tumor Associated Macrophages to develop new Anticancer Therapies in a form of a comprehensive preclinical platform. Learn more here
Poster
28/03/2023
Antitumor activity comparison of two somatostatin receptor ligands radiolabeled with Lutetium-177 (SSO110 and DOTA-TATE)
Somatostatin Receptor ligands Antitumor Activity comparison radiolabeled with Lutetium 177 alone or combined with chemotherapy in mice. Learn more here
Poster
01/11/2022
Translational pharmacology supporting biologics development in Oncology
Translational Pharmacology is responsible for connecting products of novel molecular research, such as Biologics, to the patients that need it. Learn more here.
Poster
02/09/2022
Lewis acid catalyzed chemoselective and regioselective epoxide ring opening with sulfoximines
We report Sulfoximines with the first regioselective Epoxide Ring opening; these findings broaden their Drug Discovery and design applications. Read more.
Poster
29/06/2022
In vitro pharmacological profile of Compound A
Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.
Poster
29/06/2022
In vivo PK/PD profile of Compound A
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.
Poster
08/04/2022
Lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation
Get to know more about lead optimization of radiopharmaceuticals for molecular radiotherapy and preclinical evaluation!
Poster
08/04/2022
Mouse models of hepatocellular carcinoma
Get to know more about our comprehensive & functional preclinical platform for immunotherapy research using mouse models (PDX, human transgenic mouse).